Congestive heart failure, often known as heart failure, is a medical disorder that impairs the heart muscle's ability to pump blood. Certain medical disorders, such as cardiac artery narrowing or high blood pressure, gradually weaken and stiffen the heart, making it unable to fill and pump adequately. Shortness of breath while lying down or exerting yourself, weakness, fatigue, swelling in legs, feet, and ankles, irregular and rapid heartbeat, increased urination at night, swelling of abdomen, rapid weight gain due to fluid retention, lack of appetite, nausea, decreased alertness, severe shortness of breath and coughing up pink and foamy mucus are some symptoms of heart failure.
High prevalence of heart failure has also led to various clinical trials focusing on R&D of congestive heart failure drugs. For instance, in November 2020, a clinical trial by Brigham and Women's Hospital and sponsored by Lexicon Pharmaceuticals, a biopharmaceutical company based in the U.S., reported that sotagliflozin, a combination sodium/glucose cotransporter 1 and 2 (SGLT1/2) inhibitor, resulted in a lower risk of the composite of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure than placebo. Such R&D is also expected to aid in growth of the Congestive Heart Failure Drugs Market.
Read More@ https://bit.ly/3mQKJ5h
